Payment overview · 2025
General Payments
$252.80
13 reported records · 5 companies
Healthcare provider profile · identity verified
Kumar Sathianathan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GEORGETOWN, TX · NPI 1831144161
Verified facts
What the public records show
CMS Open Payments records show Kumar Sathianathan, M.D. received $252.80 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $81.49 | 32.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.75 | 23.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.93 | 18.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.52 | 17.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.11 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.80 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.49 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $81.49 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
95 | 91 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1349 | 392 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1116 | 301 |
| Lisinopril | Lisinopril | 533 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 493 | 157 |
| Losartan Potassium | Losartan Potassium | 488 | 138 |
| Omeprazole | Omeprazole | 472 | 126 |
| Metformin Hcl | Metformin Hcl | 444 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 134 |
| Ezetimibe | Ezetimibe | 405 | 139 |
| Hydrochlorothiazide | Hydrochlorothiazide | 399 | 112 |
| Zolpidem Tartrate | Zolpidem Tartrate | 378 | 60 |
| Alprazolam | Alprazolam | 239 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 59 |
| Methylprednisolone | Methylprednisolone | 236 | 187 |
| Gabapentin | Gabapentin | 229 | 78 |
| Azithromycin | Azithromycin | 221 | 189 |
| Simvastatin | Simvastatin | 216 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 55 |
| Furosemide | Furosemide | 194 | 64 |
| Montelukast Sodium | Montelukast Sodium | 189 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 46 |
| Glipizide Er | Glipizide | 166 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 51 |
| Ozempic | Semaglutide | 162 | 32 |
| Tramadol Hcl | Tramadol Hcl | 154 | 43 |
| Clonazepam | Clonazepam | 152 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 31 |
| Jardiance | Empagliflozin | 145 | 44 |
| Trazodone Hcl | Trazodone Hcl | 143 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 133 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 33 |
| Synthroid | Levothyroxine Sodium | 119 | 28 |
| Finasteride | Finasteride | 117 | 37 |
| Allopurinol | Allopurinol | 112 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 36 |
| Paxlovid | Nirmatrelvir/Ritonavir | 95 | 91 |
| Atenolol | Atenolol | 92 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 83 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 67 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 31 |
| Mounjaro | Tirzepatide | 83 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 21 |
| Meloxicam | Meloxicam | 82 | 22 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 79 | 78 |
| Potassium Chloride | Potassium Chloride | 79 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 23 |
| Carvedilol | Carvedilol | 74 | 26 |
| Bupropion Xl | Bupropion Hcl | 71 | 20 |
| Eliquis | Apixaban | 67 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 62 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 19 |
| Prednisone | Prednisone | 59 | 50 |
| Ondansetron Odt | Ondansetron | 58 | 29 |
| Famotidine | Famotidine | 57 | 16 |
| Lorazepam | Lorazepam | 56 | 12 |
| Fenofibrate | Fenofibrate | 52 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 17 |
| Sertraline Hcl | Sertraline Hcl | 52 | 19 |
| Temazepam | Temazepam | 52 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 14 |
| Nystatin | Nystatin | 48 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Irbesartan | Irbesartan | 46 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 15 |
| Levofloxacin | Levofloxacin | 42 | 37 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 11 |
| Folic Acid | Folic Acid | 41 | 13 |
| Estradiol | Estradiol | 39 | 15 |
| Januvia | Sitagliptin Phosphate | 39 | 13 |
| Lovastatin | Lovastatin | 39 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | 17 |
| Pregabalin | Pregabalin | 37 | 11 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 17 |
| Fluconazole | Fluconazole | 35 | 27 |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Celecoxib | Celecoxib | 34 | 17 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 27 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 11 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Risperidone | Risperidone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 11 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 14 | 14 |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Cefprozil | Cefprozil | 11 | 11 |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.80 · 13 records | Amgen Inc. | Cologuard Collection Kit, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error